Overcoming drug-tolerant cancer cell subpopulations showing AXL activation and epithelial–mesenchymal transition is critical in conquering ALK-positive lung cancer

Anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) induce a dramatic response in non–small cell lung cancer (NSCLC) patients with the ALK fusion gene. However, acquired resistance to ALK-TKIs remains an inevitable problem. In this study, we aimed to discover novel therapeutic targets t...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamichi, Shinji, Seike, Masahiro, Miyanaga, Akihiko, Chiba, Mika, Zou, Fenfei, Takahashi, Akiko, Ishikawa, Arimi, Kunugi, Shinobu, Noro, Rintaro, Kubota, Kaoru, Gemma, Akihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007478/
https://www.ncbi.nlm.nih.gov/pubmed/29930762
http://dx.doi.org/10.18632/oncotarget.25531

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007478/
https://www.ncbi.nlm.nih.gov/pubmed/29930762
http://dx.doi.org/10.18632/oncotarget.25531

Ejemplares similares